Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Hematology ; (12): 450-453, 2011.
Artigo em Chinês | WPRIM | ID: wpr-251537

RESUMO

<p><b>OBJECTIVE</b>To analyze the clinical efficacy of imatinib mesylate (IM) for Ph-positive or BCR-ABL positive chronic myeloid leukemia (CML) to couple the trough plasma concentrations (C mins) of IM with clinical responses and adverse events (AEs).</p><p><b>METHODS</b>One hundred and one CML patients received IM therapy, and Cmins of IM were determined in 30 patients.</p><p><b>RESULTS</b>(1) Cumulative complete hematological response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR) and negative BCR/ABL fusion gene rates were 96.6%, 86.5%, 77.5% and 47.2%, respectively, in CML-CP patients. In accelerated and blastic phases (AP and BC) patients, CHR, MCyR, CCyR and negative BCR-ABL fusion gene rates were 58.3%, 25.0%, 25.0%, 8.3%, respectively. (2) Mean Cmins of IM was significantly higher in the CCyR at 1 year [(1472 +/- 482) microg/L] group than in the non-CCyR at 1 years group [(1067 +/- 373) microg/L] (P < 0.05), and higher in the MMR at 1 year group than in the non-MMR at 1 years group [(1624 +/- 468) microg/L vs (1137 +/- 404) microg/L, P < 0.05].</p><p><b>CONCLUSION</b>IM significantly improves cytogenetic and molecular response, event-free survival, and overall survival for patients with Ph-positive CML. The Cmins of IM exerts a significant impact on clinical response (CCyR and MMR at 1 year).</p>


Assuntos
Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Antineoplásicos , Sangue , Usos Terapêuticos , Benzamidas , Mesilato de Imatinib , Leucemia Mielogênica Crônica BCR-ABL Positiva , Sangue , Tratamento Farmacológico , Piperazinas , Sangue , Usos Terapêuticos , Pirimidinas , Sangue , Usos Terapêuticos , Resultado do Tratamento
2.
Chinese Journal of Hematology ; (12): 223-227, 2010.
Artigo em Chinês | WPRIM | ID: wpr-283878

RESUMO

<p><b>OBJECTIVE</b>To investigate the effect of DNA methylation in combination with histone deacetylase inhibitor on transcription regulation of Ras associated domain family gene 1(RASSF1A) tumor suppressor gene and the molecular biological behaviors in U266 cells.</p><p><b>METHODS</b>The U266 cells were treated with different doses of 5-Aza-2'-deoxycytidine (5-Aza-CdR) and Valproate (VPA) each alone or in combination. Methylation-specific PCR (MSP) was used to detect CpG island methylation in RASSF1A promoter. Quantitative real-time reverse transcription polymerase chain reaction (RQ-PCR) was used to examine the expression of RASSF1A gene in U266 cells. MTT was used for cell proliferation. Cell apoptosis and cell cycle were analyzed by flow cytometry.</p><p><b>RESULTS</b>The methylation of RASSF1A gene promoter was detected in U266 cells, while there was little RASSF1A gene expressing in the control group. The demethylation effect could be detected in the 5-Aza-CdR treated and combined treatment groups but no in the VPA group. The expression level of RASSF1A was induced by 5-Aza-CdR in a concentration-dependent manner while VPA had no such effect. The expression level of RASSF1A mRNA was increased significantly in the combined treatment group. Higher growth inhibition and apoptosis effects were found in 5-Aza-CdR and VPA combination group than that in 5-Aza-CdR or VPA alone group (P < 0.05). After treatment with 5-Aza-CdR or VPA alone for 72 h, more cells were arrested in G(0)/G(1) phase as conpared with control group (P < 0.05), and even more cells were so arrested in combined treatment group (P < 0.05).</p><p><b>CONCLUSION</b>DNA methylation and histone deacetylase inhibitor can synergistically induce demethylation of the RASSF1A gene, re-express RASSF1A gene silenced in U266 cells, inhibit the proliferation of U266 cells and induce cell apoptosis.</p>


Assuntos
Humanos , Linhagem Celular Tumoral , Ilhas de CpG , Metilação de DNA , Expressão Gênica , Inibidores de Histona Desacetilases , Regiões Promotoras Genéticas
3.
Journal of Experimental Hematology ; (6): 335-339, 2010.
Artigo em Chinês | WPRIM | ID: wpr-243360

RESUMO

This study was aimed to investigate the effect of CD44 gene silence on the drug resistance and biologic activity of human multidrug resistant leukemia cell line K562/A02. The oligonucleotides of CD44 gene were designed according to related data of GenBank, double-stranded DNA was produced by annealing, and was inserted into pGCsilencerU6/Neo/GFP vector. The resultant recombinant plasmid pGCsiRNA-CD44 was transfected into K562/A02 cell line. Expressions of CD44, mdr-1 and blc-2 mRNA were assayed by real time RT-PCR. The 50% inhibitory concentration (IC50) of doxorubicin (ADM) for K562/A02 cell line was determined by MTT method. Cell cycle was determined by flow cytometry. The morphology of apoptotic cells was examined by Hochst 33258 staining. The results indicated that the siRNA eukaryotic plasmid directing at CD44 gene could effectively silence the CD44 gene of K562/A02 cells; as compared with control group, the CD44 expression in K562/A02 cells transfected with 4 pGCsiRNA-CD44 plasmids was obviously inhibited, while the inhibition of CD44 expression in cells transfected with siCD44-1 was strongest. After being transfected with pGCsiRNA-CD44, the expression of CD44 mRNA in K562/A02 cells reduced by 64.1% (p<0.05), at the same time the expression of mdr-1 and bcl-2 mRNA in pGCsiRNA-CD44-transfected K562/A02 cells reduced by 25.6% and 50.8% respectively. IC50 of K562/A02 cells after transfection decreased to (8.77+/-1.63) microg/ml and was obviously lower than that of control (17.97+/-1.61) microg/ml (p<0.01). After transfection for 48 hours, the ratio of K562/A02 cells in G0/G1 increased by 10.7%, and the cells displayed karyopyknosis, nuclear margination and apoptotic bodies. It is concluded that the siRNA plasmid specifically targeting CD44 gene can remarkably down-regulate the expression of CD44 gene, inhibit K562/A02 cell proliferation, induce its apoptosis and effectively reverse the multidrug resistance of K562/A02 cells.


Assuntos
Humanos , Apoptose , Linhagem Celular Tumoral , Proliferação de Células , Resistência a Múltiplos Medicamentos , Genética , Resistencia a Medicamentos Antineoplásicos , Genética , Inativação Gênica , Vetores Genéticos , Receptores de Hialuronatos , Genética , Células K562 , RNA Interferente Pequeno
4.
Chinese Journal of Hematology ; (12): 308-311, 2008.
Artigo em Chinês | WPRIM | ID: wpr-240020

RESUMO

<p><b>OBJECTIVE</b>To quantify the CD4+ CD25+ CD127(low) regulatory T cell (Treg), the expression levels of forkhead/winged helix transcription factor FOXP3 and Notch1 mRNA in aplastic anemia (AA) patients before and after treatment, and explore the significance of Treg in pathogenesis of AA.</p><p><b>METHOD</b>CD4+ CD25+ and CD4+ CD25+ CD127(low) T cells in peripheral blood were examined with FACS in 29 AA patients at active phase, 14 at recovery phase, 11 at unrecovery phase, and 15 normal controls. The levels of FOXP3 mRNA and Notch1 mRNA expression were detected with RT-PCR, and the correlations between Treg, FOXP3 mRNA and Notchl mRNA were analyzed.</p><p><b>RESULTS</b>The percentages of peripheral activated CD4+ CD25+ T cells in AA patients at active phase (4.3 +/- 0.7)% and unrecovery phase (4.2 +/- 0.6)% were significantly higher than those in normal controls (2.4 +/- 0.8)% (P < 0.05). The proportion of these cells in AA patients at recovery phase was reduced to (2.6 +/- 0.7)% (P < 0.05), being no difference from that in control group. The number of CD4+ CD25+ CD127(low) T cells in AA patients at active phase (2.4 +/- 1.2)% and unrecovery phase (2.5 +/- 1.1)% was decreased significantly compared with those in normal controls (7.1 +/- 2.7)% (P < 0.01) and in AA patients at recovery phase (5.3 +/- 1.0)% (P < 0.01), there was no difference between the latter two groups. In active phase AA patients, the levels of FOXP3 mRNA and Notchl mRNA (0.260 +/- 0.011 and 0.018 +/- 0.005, respectively) were lower than that in control group (1.307 +/- 0.011 and 0.308 +/- 0.028, respectively) (P < 0.01 and P < 0.01). After treatment, the levels significantly increased to 1.287 +/- 0.012 and 0.281 +/- 0.013 (P < 0.01 and P < 0.01), but there was no difference with that of normal controls (P > 0.05). CD4+ CD25+ CD2(low) T cells and FOXP3 were positively related with Notchl (P < 0.01) in AA patients.</p><p><b>CONCLUSION</b>The decreased number and suppressive activity of CD4 CD25+ CD127(low) Treg cells in the peripheral blood of AA patients cause over-activation of autoreactive T cells and suppression of haematopoiesis. One of the mechanisms maybe the reduced expression of Notch1 in the target cells.</p>


Assuntos
Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Anemia Aplástica , Alergia e Imunologia , Metabolismo , Antígenos CD4 , Estudos de Casos e Controles , Fatores de Transcrição Forkhead , Genética , Metabolismo , Subunidade alfa de Receptor de Interleucina-2 , Subunidade alfa de Receptor de Interleucina-7 , RNA Mensageiro , Genética , Receptor Notch1 , Genética , Metabolismo , Linfócitos T Reguladores , Alergia e Imunologia
5.
Chinese Journal of Hematology ; (12): 515-517, 2006.
Artigo em Chinês | WPRIM | ID: wpr-243922

RESUMO

<p><b>OBJECTIVE</b>To explore the prophylactic effect of tissue inhibitor of matrix metalloproteinase (TIMP) on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a murine model.</p><p><b>METHODS</b>The murine model of aGVHD after allo-HSCT was established by using female C57BL/b (H-2b) mouse as the donor, and male BALB/c (H-2b) as the recipient. After allo-HSCT, recipient mice were divided into 3 groups. For aGVHD prophylaxis group A was given TIMP (2 mg/d) , group B CsA (5 mg x kg(-1) x d (-1)) was given, and group C nothing. Physical signs, mean survival time (MST), peripheral blood counts and aGVHD histopathology were observed.</p><p><b>RESULTS</b>Mice in group C developed typical aGVHD and 100% of mortality, with a MST of 8 days, and those in group A and B had longer survival, the MST being (4.8 +/- 1.4) d and (4.3 +/- 0.9) d respectively, with no statistical difference in peripheral blood count between these two groups. Mice in group A showed less severe signs.</p><p><b>CONCLUSIONS</b>TIMP markedly prolongs MST of allo-HSCT recipients, delays the onset of aGVHD signs, and has no adverse effect on hematopoiesis reconstitution.</p>


Assuntos
Animais , Feminino , Masculino , Camundongos , Doença Enxerto-Hospedeiro , Transplante de Células-Tronco Hematopoéticas , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Inibidores Teciduais de Metaloproteinases , Usos Terapêuticos
6.
Journal of Experimental Hematology ; (6): 59-62, 2004.
Artigo em Chinês | WPRIM | ID: wpr-278801

RESUMO

To study the mobilization of peripheral blood stem cells (PBSC) with anti-CD49d monoclonal antibody and try to find a new method for mobilization of PBSC, anti-CD49d McAb, rhG-CSF and combination of anti-CD49d McAb with rhG-CSF were administered subcutaneously to mice separately, the count of white blood cells (WBC) and percentage of CD34(+) cells in peripheral blood of donor mice were dynamically observed, CD34 positive cells obtained by above methods were transfused to recipient mice. The results showed that the count of WBC and percentage of CD34(+) cells in peripheral blood of donor mice elevated significantly after the administration of anti-CD49d McAb, rhG-CSF or combination of anti-CD49d McAb with rhG-CSF. The most effective method for mobilization is the combination of rhG-CSF with anti-CD49d McAb. Reconstitution of hematopoiesis was successful in all group recipient mice after transplantation. Most rapid hematopoietic recovery was observed in recipient mice by rhG-CSF plus anti-CD49d McAb for mabilization. In conclusion, anti-CD49d McAb is effective and synergistic with rhG-CSF in mobilization of CD34 positive cells from bone marrow into peripheral blood.


Assuntos
Animais , Feminino , Masculino , Camundongos , Anticorpos Monoclonais , Farmacologia , Antígenos CD34 , Fator Estimulador de Colônias de Granulócitos , Farmacologia , Hematopoese , Mobilização de Células-Tronco Hematopoéticas , Transplante de Células-Tronco Hematopoéticas , Integrina alfa4 , Alergia e Imunologia , Camundongos Endogâmicos BALB C , Proteínas Recombinantes
7.
Chinese Journal of Physical Medicine and Rehabilitation ; (12)2003.
Artigo em Chinês | WPRIM | ID: wpr-683069

RESUMO

Objective To investigate whether or not extracorporeal shock wave (ESW) treatment is safe for treating low back pain caused by lumbar facet joint degeneration by observing its effects on the lumbar segment of the spinal cord.Methods Five adult dogs were used for this study.ESWs were focused on their right L_(4~5) facet joints. The energy output was set at 40% of the maximum output,and a total of 1000 shocks were delivered at a frequency of 120/min.Before and 3 days after the treatment,the somatosensory evoked potentials (SEPs) induced by stimulating the tibial nerve were recorded from the animals' scalps,and the motor function of their hind limbs was evaluated with Tarlov's scale.The animals were then sacrificed and the L_(4~5) segments of their spinal cords were taken for histopatho- logical observation,with the T_(12) segments taken as controls.Results Three days after ESW treatment,the left and the right hind limbs scored 5 and 4 on the Tarlov scale.The amplitude of SEPs decreased and their latency increased. Histopathological observation showed mild swelling of the L_(4~5) segment of the spinal cord with congested veins on the surface.Erythrocyte and leukocyte exudation as well as myelin sheath swelling in the spinal cord were also observed un- der the microscope,but with no demyelination.Conclusion ESW had some adverse effects on the spinal cord when focused on the facet joint.Further studies of the safety range of ESW energy and distance are needed.

8.
Journal of Environment and Health ; (12)1992.
Artigo em Chinês | WPRIM | ID: wpr-675846

RESUMO

Objective To establish a new chemiluminescence method for determination of resorcinol in wastewater. Methods In media of acid chemiluminescence reaction of resorcinol with ceriumⅣ in the presence of Tween 40 as enhancer was investigated. A new chemiluminescence method for determination of resorcinol with flow injection technique was developed. Results The linear range for resorcinol was 8.0?10-8~5.0?10-5 mol/L with 6.0?10-8 mol/L detection limit. The relative standard deviation was 3.5% for 5.0?10-6 mol/L resorcinol in 11 parallel measurements. Conclusion This method can used to determine the content of resorcinol in wastewater of laboratory and resorcinol compound solution with satisfactory results.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA